Video

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

Author(s):

Andrew E. Hendifar, MD
Conference|ESMO Gastrointestinal Cancers Congress

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

HALO-202 is phase II study that randomized previously untreated patients with metastatic pancreatic ductal adenocarcinoma to PEGPH20 in addition to standard gemcitabine and abraxane versus standard gemcitabine and abraxane alone.

<<<

View more from the 2017 World Congress on GI Cancer

Related Videos
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Related Content
Danny Nguyen, MD
September 11th 2024

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Benjamin Besse, MD, PhD, a medical oncologist and professor of medicine at Paris Saclay University, Institut Gustave Roussy, Villejuif, France
September 11th 2024

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

John V. Heymach, MD, PhD
September 10th 2024

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

Hidehito Horinouchi, MD, PhD, medical oncologist, Department of Thoracic Oncology, National Cancer Center Hospital
September 10th 2024

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC